HRS-5346 – Talk Bio

Actionable Insights Powered by AI

Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal

4 weeks ago talkbio0Tagged Arteriosclerosis, Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, licensing agreement, Lp(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement

Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug

4 weeks ago talkbio0Tagged Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, Inhibitor, licensing agreement, Lipoprotein(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement